Research Project Database
Code: 119594
1: 119594
Title: Improving the control of Mycoplasma synoviae infection
2: Improving the control of Mycoplasma synoviae infection
Country: Hungary
3: Hungary
Funding Organisation: National Research, Development and Innovation Office
4: National Research, Development and Innovation Office
Animal Group: Chickens
Turkeys
5: Chickens
Turkeys
Pathogen: Mycobacterium spp.
6: Mycobacterium spp.
Disease: Mycoplasmosis
7: Mycoplasmosis
Category: Diagnostic test development incl. sensors
Disease pathogenesis, including pathogen biology, evolution and resistance
8: Diagnostic test development incl. sensors
Disease pathogenesis, including pathogen biology, evolution and resistance
9: 77,79
Research Organisation: Institute for Veterinary Medical Research (Centre for Agricultural Research)
10: Institute for Veterinary Medical Research (Centre for Agricultural Research)
Number of Research Staff (FTE): 9
11: 9
Principal Investigator (PI): Miklós Gyurenacz
12: Miklós Gyurenacz
Cost (Euros): 111063
13: 111063
End Date (dd/mm/yyyy): 31-10-2020
14: 1604102400
Duration (months): 48
15: 48
Link: http://aoti.agrar.mta.hu/en/projects_NKFI_K_119594
16: http://aoti.agrar.mta.hu/en/projects_NKFI_K_119594
Project objectives and deliverables with estimated delivery dates for each deliverable (if possible): Mycoplasma synoviae is an economically important pathogen of poultry causing respiratory disease, infectious synovitis and eggshell apex abnormality in chickens and turkeys. This agent has a worldwide distribution and its occurrence is increasing. Control of this disease consists of three general aspects: eradication followed by prevention, vaccination or medication.
The main aim of the present project is to improve the control of M. synoviae infection:

1) A system for the genotyping of M. synoviae isolates will be developed. It will facilitate the discovery of possible M. synoviae reservoirs and infection routes between and within the different poultry farming companies, thus it will improve the disease prevention efforts.

2) An assay to differentiate the live attenuated vaccine strain from the clinical isolates will also be developed.

3) Essential data will be presented about the antibiotic susceptibility profiles of M. synoviae strains which will help the antibiotic therapy of infections. Methods allowing rapid and cos-effective molecular detection of the antibiotic susceptibility profile of M. synoviae isolates will be developed. This will allow us to determine the antibiotic susceptibility of the clinical isolates within few hours, without culture, directly from the clinical samples (e.g. trachea swabs). Veterinary practitioners will be able to rapidly start treating M. synoviae infected flocks and choose the best antibiotic which is the most effective, less important for human medicine, has appropriate withdrawal time and lowest price. Consequently the economic losses and spreading of antibiotic resistance will be markedly reduced.
17: Mycoplasma synoviae is an economically important pathogen of poultry causing respiratory disease, infectious synovitis and eggshell apex abnormality in chickens and turkeys. This agent has a worldwide distribution and its occurrence is increasing. Control of this disease consists of three general aspects: eradication followed by prevention, vaccination or medication.
The main aim of the present project is to improve the control of M. synoviae infection:

1) A system for the genotyping of M. synoviae isolates will be developed. It will facilitate the discovery of possible M. synoviae reservoirs and infection routes between and within the different poultry farming companies, thus it will improve the disease prevention efforts.

2) An assay to differentiate the live attenuated vaccine strain from the clinical isolates will also be developed.

3) Essential data will be presented about the antibiotic susceptibility profiles of M. synoviae strains which will help the antibiotic therapy of infections. Methods allowing rapid and cos-effective molecular detection of the antibiotic susceptibility profile of M. synoviae isolates will be developed. This will allow us to determine the antibiotic susceptibility of the clinical isolates within few hours, without culture, directly from the clinical samples (e.g. trachea swabs). Veterinary practitioners will be able to rapidly start treating M. synoviae infected flocks and choose the best antibiotic which is the most effective, less important for human medicine, has appropriate withdrawal time and lowest price. Consequently the economic losses and spreading of antibiotic resistance will be markedly reduced.
FilesNo files are attached.